Presentation is loading. Please wait.

Presentation is loading. Please wait.

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Published byMargareta Arvidsson Modified over 5 years ago

Similar presentations

Presentation on theme: "Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from."— Presentation transcript:

1 Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. (A) Patient global assessment (PtGA), Pain visual analogue scale, FACIT-Fatigue (FACIT-F), Health Assessment Questionnaire-Disability Index (HAQ-DI), SF-36 physical and mental component scores (PCS and MCS), morning stiffness visual analogue scale and Rheumatoid Arthritis Impact of Disease (RAID). (B) SF-36 individual domains. *p<0.05 for the response rate relative to placebo. †p< for the response rate relative to placebo. ‡p<0.001 for the response rate relative to placebo. BP, Bodily Pain; csDMARDs, conventional synthetic disease-modifying anti-rheumatic drugs; GH, General Health perceptions; MH, Mental Health; NNT, number needed to treat; PF, Physical Functioning; RE, Role Emotional; RP, Role Physical; SF, Social Functioning; VT, Vitality. Vibeke Strand et al. RMD Open 2017;3:e000416 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from."

Similar presentations

Volume 42, Issue 5, Pages (May 2005)

Volume 42, Issue 5, Pages (May 2005)
Triangles and dotted lines are for mean values. , P <

Triangles and dotted lines are for mean values. , P <
Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.

Proportion of patients reporting scores ≥age-matched and gender-matched normative PRO values at baseline and 24 weeks in the (A) AMBITION and (B) ADACTA.
Psychosocial Correlates of Symptoms in Functional Dyspepsia

Psychosocial Correlates of Symptoms in Functional Dyspepsia
Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.

Mean changes in the Short Form-36 subscales from baseline values for combined pulmonary fibrosis and emphysema (CPFE) (n=16), and chronic obstructive pulmonary.
Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI

Mean change from baseline in (A) DAS28-4(ESR), (B) CDAI and (C) HAQ-DI
Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.

Mean change in patient-reported outcomes from baseline to Week 25 with biweekly or monthly pegloticase compared with placebo. Mean change in patient-reported.
Clinical Epidemiology and Global Health

Clinical Epidemiology and Global Health
Health-Related Quality-of-Life Measures: Evidence from Tunisian Population Using the SF-12 Health Survey  Moheddine Younsi, PhD  Value in Health Regional.

Health-Related Quality-of-Life Measures: Evidence from Tunisian Population Using the SF-12 Health Survey  Moheddine Younsi, PhD  Value in Health Regional.
Volume 61, Issue 5, Pages (November 2014)

Volume 61, Issue 5, Pages (November 2014)
The Impact of Pain Management on Quality of Life

The Impact of Pain Management on Quality of Life
Postoperative pain after abdominal hysterectomy: a randomized, double-blind, controlled trial comparing continuous infusion vs patient-controlled intraperitoneal.

Postoperative pain after abdominal hysterectomy: a randomized, double-blind, controlled trial comparing continuous infusion vs patient-controlled intraperitoneal.
Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement  J.M. Quintana, Ph.D., A. Escobar, M.D., A. Bilbao,

Responsiveness and clinically important differences for the WOMAC and SF-36 after hip joint replacement  J.M. Quintana, Ph.D., A. Escobar, M.D., A. Bilbao,
Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement  A. Escobar, M.D., J.M. Quintana, Ph.D., A. Bilbao,

Responsiveness and clinically important differences for the WOMAC and SF-36 after total knee replacement  A. Escobar, M.D., J.M. Quintana, Ph.D., A. Bilbao,
Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity  Nina K. Grewal,

Quantity of clot lysed after catheter-directed thrombolysis for iliofemoral deep venous thrombosis correlates with postthrombotic morbidity  Nina K. Grewal,
Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)

Mean DAS (A), HAQ (B) and percentages in low disease activity, DAS remission and drug-free DAS remission (C) during 5 years in the DAS ≤2.4 steered (BeSt)
Changes in evaluation indicators from baseline to 12 weeks per visit.

Changes in evaluation indicators from baseline to 12 weeks per visit.
Comparison of recovery after mitral valve repair and replacement

Comparison of recovery after mitral valve repair and replacement
Mu Qin et al. JACEP 2017;j.jacep

Mu Qin et al. JACEP 2017;j.jacep
Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Clinical, functional and radiographic outcomes following up to 3 years of open-label adalimumab as monotherapy after 2 years of adalimumab+methotrexate.

Similar presentations

Ads by Google